Company Overview of Ontario Institute For Cancer Research
101 College St Suite 800
Toronto, ON M5g 1l7
Founded in 2001
Key Executives for Ontario Institute For Cancer Research
President and Scientific Director
Deputy Director and Chief Scientific Officer
Compensation as of Fiscal Year 2014.
Ontario Institute For Cancer Research Key Developments
Ontario Institute For Cancer Research Presents at BioJapan 2013 World Business Forum, Oct-09-2013
Sep 25 13
Ontario Institute For Cancer Research Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.
Ontario Institute for Cancer Research Appoints Robert N. Klein to the Board of Directors
Jun 20 13
The Board of Directors of the Ontario Institute for Cancer Research announced the appointment of Robert N. Klein to OICR's Board of Directors. He served as Chairman of the Governing Board of CIRM for its first seven years and was elected Chairman Emeritus for the organization in 2011.
Canadian Partnership Against Cancer Selects Ontario Institute For Cancer Research as Coordinating Centre for Canadian Cancer Clinical Trials
Apr 25 13
Ontario Institute For Cancer Research (OICR) announced that OICR has been selected by the Canadian Partnership Against Cancer (CPAC) to develop the coordinating centre for the Canadian Cancer Clinical Trials Network (CCCTN). Dr. Janet Dancey, OICR's Director of the High Impact Clinical Trials Program, will be the Scientific Director and lead the CCCTN coordinating centre. The collaborating organizations are the NCIC Clinical Trials Group and N2 (Network of Networks). The pan-Canadian Network was established following a competitive application process adjudicated by an international panel. It will improve the efficiency and quality of clinical trials by providing coordination and support for a network of clinical trial teams at cancer treatment centres and hospitals across Canada. The support for clinical trial conduct will include ethics, regulatory, biospecimen collection and analyses, and knowledge transfer. The Network will improve the lives of cancer patients and individuals at risk for cancer. It will build on and help support the activities associated with clinical trials expertise already existing in the country. The result will be an increase in the clinical research capacity of Canadian cancer centres to effectively conduct cancer clinical trials sponsored by academic institutions or cooperative clinical trials groups that will address questions of great importance to Canadians and the Canadian health care system. The coordinating centre will serve as the administrative hub of the CCCTN. The Network will develop and implement common tools and resources that will improve the quality of clinical trials and facilitate their timely execution. Providing support for personnel in treatment centres and hospitals in the network will make it possible to conduct more trials. It is expected that the number of cancer clinical trials in Canada and the number of patients enrolled will increase as a result of the activities of the CCCTN.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries